Skip to main content

Furosemide Disease Interactions

There are 9 disease interactions with furosemide.

Major

Loop diuretics (applies to furosemide) anuria

Major Potential Hazard, High plausibility.

The use of loop diuretics is contraindicated in patients with anuria.

References

  1. (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
  2. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  3. "Product Information. Demadex (torsemide)." Boehringer Mannheim
  4. (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
View all 4 references
Major

Loop diuretics (applies to furosemide) cirrhosis

Major Potential Hazard, High plausibility. Applicable conditions: Hepatic Coma

Loop diuretic therapy should be initiated in the hospital under strict observation in patients with liver cirrhosis and ascites. Sudden alteration of fluid and electrolyte balance may precipitate hepatic encephalopathy and coma in such patients, who are also at increased risk for the development of hypokalemia. Supplemental potassium and/or concomitant use of an aldosterone antagonist or potassium-sparing agent may help prevent hypokalemia and metabolic alkalosis. Loop diuretics should be withheld in patients with hepatic coma until the condition improves.

References

  1. Ring-Larsen H (1974) "Bumetanide in the treatment of hepatic ascites. A short and long-term study." Acta Med Scand, 195, p. 411-4
  2. (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
  3. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  4. "Product Information. Demadex (torsemide)." Boehringer Mannheim
  5. Schwartz FD, Pillay VK, Kark RM (1970) "Ethacrynic acid: its usefulness and untoward effects." Am Heart J, 79, p. 427-8
  6. Lieberman FL, Reynolds TB (1965) "The use of ethacrynic acid in patients with cirrhosis and ascites." Gastroenterology, 49, p. 531-8
  7. (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
  8. Knauf H, Mutschler E (1994) "Liver cirrhosis with ascites: pathogenesis of resistance to diuretics and long-term efficacy and safety of torasemide." Cardiology, 84, p. 87-98
View all 8 references
Major

Loop diuretics (applies to furosemide) electrolyte losses

Major Potential Hazard, High plausibility. Applicable conditions: Hypocalcemia, Hypokalemia, Hyponatremia, Magnesium Imbalance, Diarrhea, Electrolyte Abnormalities, Hyperaldosteronism, Malnourished, Ventricular Arrhythmia, Vomiting, Dehydration

The use of loop diuretics, particularly at high dosages or during chronic therapy, is commonly associated with loss of electrolytes, including potassium, sodium, chloride, magnesium, and calcium. Potassium and magnesium depletion may lead to cardiac arrhythmias and cardiac arrest. Other electrolyte-related complications include metabolic alkalosis and hyponatremia, which are rarely life-threatening. Excessive diuresis, as indicated by rapid weight loss, may induce dehydration and hypovolemia, which can result in acute hypotension, orthostasis, circulatory collapse, vascular thrombosis and embolism, and abrupt reduction in glomerular filtration and renal blood flow. Severe dehydration is most likely to occur in the elderly and patients under prolonged sodium restriction. Therapy with loop diuretics should be administered cautiously in patients with or predisposed to fluid and electrolyte depletion, including patients with primary or secondary aldosteronism (may have low potassium levels); those with severe or prolonged diarrhea or vomiting; and those with poor nutritional status. Fluid and electrolyte abnormalities should be corrected before initiating therapy, and blood pressure as well as serum electrolyte concentrations monitored periodically and maintained at normal ranges during therapy. Patients should be advised to immediately report signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting. Digitalized patients and patients with a history of ventricular arrhythmias should be monitored carefully, since the development of hypokalemia may be particularly dangerous in these patients. The risk of hypokalemia may be minimized by slow diuresis, a lower diuretic dosage, potassium supplementation, or combined use with a potassium-sparing diuretic. Similarly, to prevent excessive dehydration and hyponatremia, sodium intake should be liberalized if clinically feasible.

References

  1. Tambyah JA, Lim MK (1969) "Effect of furesomide on calcium excretion." Br Med J, 03/22/69, p. 751-2
  2. Roesner M (1986) "The loop diuretics: focus on furosemide and ethacrynic acid." N C Med J, 47, p. 93-6
  3. Ponto LL, Schoenwald RD (1990) "Furosemide (frusemide): a pharmacokinetic/pharmacodynamic review." Clin Pharmacokinet, 18, p. 381-408
  4. Ward A, Heel RC (1984) "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs, 28, p. 426-64
  5. Menday AP, Adnitt PI, Underwood PN (1991) "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp, 50, p. 57-64
  6. Kubik MM, Bowers E, Underwood PN (1976) "Longterm experience of the routine use of bumetanide." Br J Clin Pract, 30, p. 11-4
  7. (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
  8. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  9. "Product Information. Demadex (torsemide)." Boehringer Mannheim
  10. Schwartz AB (1975) "Diuretic-induced hypokalemia." Am Fam Physician, 11, p. 101-4
  11. Cooperman LB, Rubin IL (1973) "Toxicity of ethacrynic acid and furosemide." Am Heart J, 85, p. 831-4
  12. Schwartz FD, Pillay VK, Kark RM (1970) "Ethacrynic acid: its usefulness and untoward effects." Am Heart J, 79, p. 427-8
  13. DeRubertis FR, Michelis MF, Beck N, Davis BB (1970) "Complications of diuretic therapy: severe alkalosis and syndrome resembling inappropriate secretion of antidiuretic hormone." Metabolism, 19, p. 709-19
  14. Sullivan RC, Freemon FR, Caranasos GJ (1971) "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J, 64, p. 869-72
  15. Plumb VJ, James TN (1978) "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis, 47, p. 91-4
  16. Schmidt P, Friedman IS (1967) "Adverse effects of ethacrynic acid." N Y State J Med, 67, p. 1438-42
  17. Martinez-Maldonado M (1973) "Electrolyte disturbances resulting from diuretic therapy." Tex Med, 69, p. 83-7
  18. Gaillard R, Vallotton B, Muller F (1974) "Letter: Hypotension after angiotensin-II infusion and hypovolaemia induced by diuretic." Lancet, 1, p. 1349
  19. White SJ, Williamson K (1979) "What to watch for when you give loop diuretics." RN, 42, p. 25-7
  20. (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
  21. Patterson JH, Adams KF, Applefeld MM, Corder CN, Masse BR (1994) "Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion." Pharmacotherapy, 14, p. 514-21
  22. Oberbauer R, Krivanek P, Turnheim K (1995) "Pharmacokinetics and pharmacodynamics of the diuretic bumetanide in the elderly." Clin Pharmacol Ther, 57, p. 42-51
  23. Dunn CJ, Fitton A, Brogden RN (1995) "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs, 49, p. 121-42
  24. Blose JS, Adams KF, Patterson JH (1995) "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother, 29, p. 396-402
  25. Fowler SF, Murray KM (1995) "Torsemide: a new loop diuretic." Am J Health Syst Pharm, 52, p. 1771-80
  26. Palmer BF, Gates JR, Lader M (2003) "Causes and management of hyponatremia." Ann Pharmacother, 37, p. 1694-702
View all 26 references
Major

Loop diuretics (applies to furosemide) ototoxicity

Major Potential Hazard, High plausibility. Applicable conditions: Hearing Loss

Tinnitus and hearing loss, both reversible and permanent, have been reported with the use of loop diuretics. Ototoxic effects have generally been associated with rapid intravenous or intramuscular injection, severe renal impairment, unusually high dosages (i.e. several times the usual recommended dosages), and/or concomitant use of other ototoxic agents. Therapy with loop diuretics should be administered cautiously in patients with preexisting vestibular and/or auditory impairment, since it may delay the recognition or confound the diagnosis of a drug-induced ototoxic effect. High-dose parenteral therapy should be administered as controlled infusion.

References

  1. Boston Collaborative Drug Surveillance Program (1973) "Drug-induced deafness." JAMA, 224, p. 515-6
  2. (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
  3. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  4. Vargish T, Benjamin R, Shenkman L (1970) "Deafness from furosemide." Ann Intern Med, 72, p. 761
  5. Quick CA, Hoppe W (1975) "Permanent deafness associated with furosemide administration." Ann Otol Rhinol Laryngol, 84, p. 94-101
  6. David D, Hitzig P (1971) "Diuretics and ototoxicity." N Engl J Med, 284, p. 1328
  7. Heidland A, Wigand N (1970) "Influence of high doses of furosemide on hearing of uremic patients." Klin Wochenschr, 48, p. 1052
  8. Lloyd-Mostyn R, Lord I (1971) "Ototoxicity of intravenous furosemide." Lancet, 2, p. 1156
  9. Schwartz G (1970) "Ototoxicity induced by furosemide." N Engl J Med, 282, p. 1413
  10. Venkateswaran P (1971) "Transient deafness from high doses of furosemide." Br Med J, 4, p. 113
  11. "Product Information. Demadex (torsemide)." Boehringer Mannheim
  12. Cooperman LB, Rubin IL (1973) "Toxicity of ethacrynic acid and furosemide." Am Heart J, 85, p. 831-4
  13. Schwartz FD, Pillay VK, Kark RM (1970) "Ethacrynic acid: its usefulness and untoward effects." Am Heart J, 79, p. 427-8
  14. Schneider WJ, Becker EL (1966) "Acute transient hearing loss after ethacrynic acid therapy." Arch Intern Med, 117, p. 715-7
  15. Matz GJ, Beal DD, Krames L (1969) "Ototoxicity of ethacrynic acid. Demonstrated in a human temporal bone." Arch Otolaryngol, 90, p. 152-5
  16. Rybak LP (1988) "Ototoxicity of ethacrynic acid (a persistent clinical problem)." J Laryngol Otol, 102, p. 518-20
  17. Meriwether WD, Mangi RJ, Serpick AA (1971) "Deafness following standard intravenous dose of ethacrynic acid." JAMA, 216, p. 795-8
  18. Merrill JP (1970) "Hazards of ethacrynic acid." JAMA, 212, p. 159
  19. Chaffee WG Jr (1970) "Hazards of ethacrynic acid." JAMA, 212, p. 159
  20. Matz GJ, Naunton RF (1968) "Ototoxic drugs and poor renal function." JAMA, 206, p. 2119
  21. Pillay VK, Schwartz FD, Aimi K, Kark RM (1969) "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet, 1, p. 77-9
  22. Ng PS, Conley CE, Ing TS (1969) "Deafness after ethacrynic acid." Lancet, 1, p. 673-4
  23. Matz GJ (1976) "The ototoxic effects of ethacrynic acid in man and animals." Laryngoscope, 86, p. 1065-86
  24. Quick CA, Duvall AJ 3d (1970) "Early changes in the cochlear duct from ethacrynic acid: an electronmicroscopie evaluation." Laryngoscope, 80, p. 954-65
  25. Hybels RL (1979) "Drug toxicity of the inner ear." Med Clin North Am, 63, p. 309-19
  26. Gomolin IH, Garschick E (1980) "Ethacrynic acid-induced deafness accompanied by nystagmus." N Engl J Med, 303, p. 702
  27. Homer MJ (1971) "Deafness after ethacrynic acid." N Engl J Med, 285, p. 1152
  28. David DS, Hitzig P (1971) "Diuretics and ototoxicity." N Engl J Med, 284, p. 1328-9
  29. Marlowe FI (1978) "Ototoxic agents." Otolaryngol Clin North Am, 11, p. 791-800
  30. Rybak LP (1993) "Ototoxicity of loop diuretics." Otolaryngol Clin North Am, 26, p. 829-44
  31. Sheffield PA, Turner JS Jr (1971) "Ototoxic drugs: a review of clinical aspects, histopathologic changes and mechanisms of action." South Med J, 64, p. 359-63
  32. Arnold W, Nadol JB Jr, Weidauer H (1981) "Ultrastructural histopathology in a case of human ototoxicity due to loop diuretics." Acta Otolaryngol (Stockh), 91, p. 399-414
  33. Ballantyne J (1973) "Ototoxicity: a clinical review." Audiology, 12, p. 325-36
  34. Beauchamp GD, Crouch TC (1975) "Deafness. Review of intravenous ethacrynic acid." J Kans Med Soc, 76, 166-8,180
  35. Ajodhia JM, Dix MR (1976) "Drug-induced deafness and its treatment." Practitioner, 216, p. 561-70
  36. (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
  37. Dunn CJ, Fitton A, Brogden RN (1995) "Torasemide: an update of its pharmacological properties and therapeutic efficacy." Drugs, 49, p. 121-42
  38. Blose JS, Adams KF, Patterson JH (1995) "Torsemide: a pyridine-sulfonylurea loop diuretic." Ann Pharmacother, 29, p. 396-402
  39. Fowler SF, Murray KM (1995) "Torsemide: a new loop diuretic." Am J Health Syst Pharm, 52, p. 1771-80
View all 39 references
Major

Loop diuretics (applies to furosemide) renal dysfunction

Major Potential Hazard, High plausibility.

Impaired effectiveness and possible delayed excretion of loop diuretics may occur in patients with severe renal dysfunction. These individuals may require high dosages that are associated with an increased risk of electrolyte abnormalities (hyponatremia, hypochloremic alkalosis, hypokalemia, hypomagnesemia, hypocalcemia) and ototoxicity (tinnitus, hearing loss). Therapy with loop diuretics should be administered cautiously in patients with significantly impaired renal function. Prolongation of the dosing intervals may be appropriate to prevent drug accumulation. The patient should be monitored closely for the signs and symptoms of fluid or electrolyte imbalance, including dry mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pains or cramps, muscular fatigue, hypotension, oliguria, tachycardia, arrhythmia, or gastrointestinal disturbances such as nausea and vomiting. Excessive diuresis should be avoided as it may induce dehydration and hypovolemia, which can result in an abrupt reduction in glomerular filtration and renal blood flow. If increasing azotemia and oliguria occur during treatment of severe progressive renal disease, or if renal function becomes progressively worse as indicated by rising BUN or serum creatinine levels, an interruption or discontinuation of therapy should be considered.

References

  1. Huang CM, Atkinson AJ, Levin M, et al. (1974) "Pharmacokinetics of furosemide in advanced renal failure." Clin Pharmacol Ther, 16, p. 659-66
  2. Cutler RE, Forrey AW, Christopher TG, Kimpel BM (1974) "Pharmacokinetics of furosemide in normal subjects and functionally anephric patients." Clin Pharmacol Ther, 15, p. 588-96
  3. Rose HJ, O'Malley K, Pruitt AW (1976) "Depression of renal clearance of furosemide in man by azotemia." Clin Pharmacol Ther, 21, p. 141-6
  4. Beermann B, Dalen E, Lindstrom B (1977) "Elimination of furosemide in healthy subjects and in those with renal failure." Clin Pharmacol Ther, 22, p. 70-8
  5. Tilstone WJ, Fine A (1978) "Furosemide kinetics in renal failure." Clin Pharmacol Ther, 23, p. 644-50
  6. Rane A, Villeneuve JP, Stone WJ, et al. (1978) "Plasma binding and disposition of furosemide in the nephrotic syndrome and in uremia." Clin Pharmacol Ther, 24, p. 199-207
  7. Andreasen F, Hansen HE, Mikkelsen E (1978) "Pharmacokinetics of furosemide in anephric patients and in normal subjects." Eur J Clin Pharmacol, 13, p. 41-8
  8. Keller E, Hoppe-Seyler G, Mumm R, Schollmeyer P (1981) "Influence of hepatic cirrhosis and end-stage renal disease on pharmacokinetics and pharmacodynamics of furosemide." Eur J Clin Pharmacol, 20, p. 27-33
  9. Donatucci CF, Deshon GE, Wade CE, Hunt M (1990) "Furosemide-induced disturbances of renal function in patients undergoing TURP." Urology, 35, p. 295-300
  10. Keller E, Hoppe-Seyler G, Schollmeyer P (1982) "Disposition and diuretic effect of furosemide in the nephrotic syndrome." Clin Pharmacol Ther, 32, p. 442-9
  11. Ward A, Heel RC (1984) "Bumetanide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use." Drugs, 28, p. 426-64
  12. Menday AP, Adnitt PI, Underwood PN (1991) "Effect of long-term treatment with bumetanide/amiloride on electrolytes and renal function in elderly patients with heart failure." Curr Ther Res Clin Exp, 50, p. 57-64
  13. Pentikainen PJ, Pasternack A, Lampainen E, Neuvonen PJ, Penttila A (1985) "Bumetanide kinetics in renal failure." Clin Pharmacol Ther, 37, p. 582-8
  14. Marcantonio LA, Auld WH, Murdoch WR, Purohit R, Skellern GG, Howes CA (1983) "The pharmacokinetics and pharmacodynamics of the diuretic bumetanide in hepatic and renal disease." Br J Clin Pharmacol, 15, p. 245-52
  15. Berg KJ, Tromsdal A, Wideroe TE (1976) "Diuretic action of bumetanide in advanced chronic renal insufficiency." Eur J Clin Pharmacol, 9, p. 265-75
  16. Lowenthal DT, Dickerman D (1983) "The use of diuretics in varying degrees of renal impairment: an overview." Clin Exp Hypertens A, 5, p. 297-307
  17. (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
  18. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  19. "Product Information. Demadex (torsemide)." Boehringer Mannheim
  20. Matz GJ, Naunton RF (1968) "Ototoxic drugs and poor renal function." JAMA, 206, p. 2119
  21. Pillay VK, Schwartz FD, Aimi K, Kark RM (1969) "Transient and permanent deafness following treatment with ethacrynic acid in renal failure." Lancet, 1, p. 77-9
  22. Kaye M, Dufresne L, McDade D (1968) "Ethacrynic acid in acute renal failure." Lancet, 1, p. 1255
  23. Sullivan RC, Freemon FR, Caranasos GJ (1971) "Complications from diuretic therapy with ethacrynic acid and furosemide." South Med J, 64, p. 869-72
  24. Plumb VJ, James TN (1978) "Clinical hazards of powerful diuretics. Furosemide and ethacrynic acid." Mod Concepts Cardiovasc Dis, 47, p. 91-4
  25. White SJ, Williamson K (1979) "What to watch for when you give loop diuretics." RN, 42, p. 25-7
  26. (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
  27. Risler T, Schwab A, Kramer B, Braun N, Erley C (1994) "Comparative pharmacokinetics and pharmacodynamics of loop diuretics in renal failure." Cardiology, 84, p. 155-61
  28. Russo D, Minutolo R, Andreucci VE (1994) "Role of loop diuretics in chronic renal failure." Cardiology, 84, p. 162-70
View all 28 references
Moderate

Furosemide (applies to furosemide) lupus erythematosus

Moderate Potential Hazard, Moderate plausibility.

The use of furosemide has been associated with exacerbation or activation of systemic lupus erythematosus. Therapy with furosemide should be administered cautiously in patients with a history of lupus.

References

  1. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
Moderate

Loop diuretics (applies to furosemide) diabetes

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Diabetes Mellitus, Abnormal Glucose Tolerance

Loop diuretics may cause hyperglycemia, glycosuria, and alterations in glucose tolerance tests. Rarely, precipitation of diabetes mellitus has been reported. Therapy with loop diuretics should be administered cautiously in patients with diabetes mellitus, glucose intolerance, or a predisposition to hyperglycemia. Patients with diabetes mellitus should be monitored more closely during therapy, and their antidiabetic regimen adjusted accordingly.

References

  1. Chaudhuri ML, Catania J (1988) "A comparison of the effects of bumetanide (Burinex) and frusemide on carbohydrate metabolism in the elderly." Br J Clin Pract, 42, p. 427-9
  2. Andersen OO, Persson I (1968) "Carbohydrate metabolism during treatment with chlorthalidone and ethacrynic acid." Br Med J, 2, p. 798-801
  3. Gray GM (1973) "Drugs, malnutrition, and carbohydrate absorption." Am J Clin Nutr, 26, p. 121-4
  4. (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
  5. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  6. Dimitriadis G, Tegos C, Golfinopoulou L, Roboti C, Raptis S (1993) "Furosemide-induced hyperglycaemia - the implication of glycolytic kinases." Horm Metab Res, 25, p. 557-9
  7. "Product Information. Demadex (torsemide)." Boehringer Mannheim
  8. Domenet JG (1968) "Diabetogenic effect of oral diuretics." Br Med J, 3, p. 188
  9. Coni NK, Gordon PW, Mukherjee AP, Read PR (1974) "The effect of frusemide and ethacrynic acid on carbohydrate metabolism." Age Ageing, 3, p. 85-90
  10. (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
View all 10 references
Moderate

Loop diuretics (applies to furosemide) hyperuricemia

Moderate Potential Hazard, High plausibility. Applicable conditions: Gout

Loop diuretics may decrease the rate of uric acid excretion. Hyperuricemia can occur but is usually asymptomatic and rarely leads to clinical gout except in patients with a history of gout or chronic renal failure. Therapy with loop diuretics should be administered cautiously in such patients.

References

  1. (2002) "Product Information. Bumex (bumetanide)." Roche Laboratories
  2. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  3. "Product Information. Demadex (torsemide)." Boehringer Mannheim
  4. (2001) "Product Information. Edecrin (ethacrynic acid)." Merck & Co., Inc
View all 4 references
Moderate

Loop diuretics (applies to furosemide) urinary retention

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Cauda Equina Syndrome w/ Neurogenic Bladder, Benign Prostatic Hyperplasia

The use of loop diuretics can cause urinary retention in patients with bladder emptying disorders, prostate hyperplasia, narrowing of the urethra. Caution and monitoring is recommended when using loop diuretics in these patients, especially when commencing therapy.

References

  1. (2007) "Product Information. Lasix (furosemide)." sanofi-aventis
  2. "Product Information. Demadex (torsemide)." Boehringer Mannheim

Furosemide drug interactions

There are 496 drug interactions with furosemide.

Furosemide alcohol/food interactions

There is 1 alcohol/food interaction with furosemide.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.